Pasireotide-induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment.

Masato Shikata,Kenji Ashida,Yuka Goto,Ayako Nagayama,Shimpei Iwata,Mamiko Yano,Nao Hasuzawa,Kento Hara,Kazutoshi Mawatari,Kiyohiko Sakata,Munehisa Tsuruta,Nobuhiko Wada,Masatoshi Nomura

Clinical case reports（2020）

引用 1|浏览13

暂无评分

摘要

Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type-5 stimulation. GLP-1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide administration.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要